<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2010-10-19 08:27:08Food and Drug Administration Pharmaceutical sciences Medical informatics Structured Product Labeling Pharmaceutical industry Adalimumab Biologic License Application BLA Center for Drug Evaluation and Research Medicine Health Pharmacology |
Add to Reading List |
DOCUMENT INFORMATION PAGE | CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017DocID: 1ueGS - View Document |
| CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEWDocID: 1t19G - View Document |
| CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEWDocID: 1sZi5 - View Document |
| MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCHDocID: 1sPXO - View Document |
| Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire ADocID: 1swgc - View Document |